COMPASS Pathways develops investigational psychedelic-based therapies for hard-to-treat mental health conditions. Its lead program, COMP360, is a synthetic psilocybin formulation studied mainly for treatment-resistant depression under clinical supervision. The company focuses on regulated, evidence-based use of psychedelics rather than consumer wellness products, aiming at patients who have not responded adequately to standard antidepressants.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -17.9 | — |
| Q2 2025 | 0 | — | -38.4 | — |
| Q3 2025 | 0 | — | -137.7 | — |
| Q4 2025 | 0 | — | -93.9 | — |
| Q1 2026 | 0 | — | 77.6 | — |
| Q2 2026 | 0 | — | -253.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Mega Fortune Company Limited (MGRT), Korsana Biosciences, Inc. (KRSA), J&J Snack Foods Corp. (JJSF), Capital Southwest Corporation (CSWC), Alkami Technology, Inc. (ALKT), The Pennant Group, Inc. (PNTG)